资讯

Endpoints News48 分钟
In race with Merus, Bicara makes the case for two-year sur­vival da­ta
Bicara presents survival data for ficerafusp alfa + Keytruda in head/neck cancer: 21.3 months median OS, 46% 2-year OS rate ...